GlassScriptPhysician profile
Ross Michael Hamilton
NPI 1538587852
$5,684.25
in general payments reported to CMS, 2019-2025
24 companies · $4,415 in 2025
The $4,415 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,269 · 2025: $4,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,684.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,482.33 | 2024-2025 | |
| Sk Life Science, INC. | $1,063.57 | 2024-2025 | Xcopri |
| Ucb, INC. | $906.17 | 2024-2025 | Briviact, Nayzilam, Fintepla |
| Biogen, INC. | $339.92 | 2024-2025 | Leqembi, Vumerity |
| Eisai INC. | $303.47 | 2025 | |
| Pfizer INC. | $294.03 | 2024-2025 | |
| Emd Serono, INC. | $246.14 | 2025 | Mavenclad |
| Lundbeck LLC | $217.73 | 2024-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $132.52 | 2024-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $98.80 | 2025 | |
| Lilly USA, LLC | $84.93 | 2024-2025 | Kisunla, Amyvid |
| Averitas Pharma INC. | $84.57 | 2024 | Qutenza |
| Alexion Pharmaceuticals, INC. | $80.80 | 2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $78.26 | 2024-2025 | Austedo Xr, Austedo Xr |
| Impel Pharmaceuticals LLC | $51.42 | 2024-2025 | Trudhesa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $41.06 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $32.29 | 2025 | Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $26.17 | 2024 | Ingrezza |
| Azurity Pharmaceuticals, INC. | $24.50 | 2025 | Zonisade |
| Philips North America LLC | $23.75 | 2024 | (Ck4) Mcot |
| Amneal Pharmaceuticals LLC | $19.97 | 2025 | Crexont |
| Janssen Biotech, INC. | $18.82 | 2025 | |
| Mdd US Operations, LLC | $18.60 | 2024 | Gocovri |
| Mallinckrodt Hospital Products INC. | $14.43 | 2024 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.